155 related articles for article (PubMed ID: 25161377)
1. Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study.
Setiani Agus L; Effendi I; Abdillah S
Saudi Pharm J; 2014 Sep; 22(4):333-7. PubMed ID: 25161377
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
5. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
9. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
11. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
12. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
13. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
[TBL] [Abstract][Full Text] [Related]
14. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
Gasu V; Ashong M; Seferi A; Fitzpatrick A
JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
[TBL] [Abstract][Full Text] [Related]
16. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
17. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
[TBL] [Abstract][Full Text] [Related]
19. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
Oettinger CW; Oliver JC; Macon EJ
J Am Soc Nephrol; 1992 Oct; 3(4):995-1001. PubMed ID: 1450373
[TBL] [Abstract][Full Text] [Related]
20. Use of Phosphate Binders in End-Stage Renal Disease: An Experience From a Secondary Care Hospital in United Arab Emirates.
Rabbani SA; Sridhar SB; Rao PGM; Kurian MT; Essawy BE
J Pharm Bioallied Sci; 2019; 11(2):148-154. PubMed ID: 31148891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]